Involved field radiotherapy for limited stage Hodgkin lymphoma: Balancing treatment efficacy against long-term toxicities

Hematological Oncology

Volumn 27, Issue 3, 2009, Pages 115-122

  Goda, Jayant S ^a   Tsang, Richard W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Hodgkin lymphoma; Involved field radiotherapy; Limited stage

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CD20 ANTIBODY; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; MANTLE FIELD RADIOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 70350747770     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.890     Document Type: Review

References (62)

1. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357(19): 1916-1927. (Pubitemid 350074687)
2. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16(3): 830-843. (Pubitemid 28108714)
3. Gospodarowicz MK, Sutcliffe SB, Clark RM, et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 1992; 22(5): 859-865.
4. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23(21): 4634-4642.
5. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin's lymphoma: results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21(19): 3601-3608. (Pubitemid 46594052)
6. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22(14): 2835-2841. (Pubitemid 41079901)
7. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79(3): 270-277. (Pubitemid 44109907)
8. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860-1861.
9. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636. (Pubitemid 19272832)
10. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005; 23(26): 6400-6408.
11. Kaplan HS, Rosenberg SA. The treatment of Hodgkin's disease. Med Clin North Am 1966; 50(6): 1591-1610.
12. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford Vand radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20(3): 630-637. (Pubitemid 34111368)
13. Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classi- fication of Tumours of Haematopoietic and Lymphoid Tissues (4th edn). IARC Press: Lyon, France, 2008.
14. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17(3): 776-783. (Pubitemid 29109305)
15. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26(3): 434-439. (Pubitemid 351171696)
16. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma. Cancer 2005; 104(6): 1221-1229.
17. Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 2002; 8(5): 377-383.
18. Regula DP Jr, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988; 318(4): 214-219.
19. Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15(9): 3060-3066. (Pubitemid 27377497)
20. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16(10): 1683-1687. (Pubitemid 41510144)
21. Savage KJ, Hoskins P, Klasa R, et al. ABVD chemotherapy is essential for optimal treatment of limited stage nodular lymphocyte predominant Hodgkin lymphoma. Hematologica 2007; 92(S5): 27-28.
22. Vijayakumar S, Myrianthopoulos LC. An updated doseresponse analysis in Hodgkin's disease. Radiother Oncol 1992; 24(1): 1-13.
23. Brincker H, Bentzen SM. A re-analysis of available doseresponse and time-dose data in Hodgkin's disease. Radiother Oncol 1994; 30(3): 227-230. (Pubitemid 24107516)
24. Duhmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19(11): 2905-2914. (Pubitemid 32538201)
25. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19(22): 4238-4244. (Pubitemid 33081641)
26. Eich H, Mueller R, Engert A, et al. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles of ABVD in early stage Hodgkin's lymphoma: interim analysis of the German Hodgkin Study Group Trial HD10. Int J Radiat Oncol Biol Phys 2005; 63 (Suppl 1(2)): S1.
27. Klasa RJ, Connors JM, Gascoyne RD, Hoskins P, Shenkier T, Voss N. Brief chemotherapy (CT) with involved field (IFRT) or extended field (EFRT) radiation after clinical staging (CS) are equivalent and both superior to EFRT alone following laparotomy staging (PS IA, IIA) in limited Hodgkin's lymphoma (HL). Leukemia and Lymphoma 2001; 42(S2): 51. Abstract p-087.
28. Radford JA, Williams MV, Hancock BW, et al. Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Eur J Haematol 2004; 73 (Suppl 65): 39.
29. Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 1997; 15(6): 2275-2287. (Pubitemid 27251129)
30. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl 2005; 66: 90-97. (Pubitemid 40873984)
31. Koontz BF, Kirkpatrick JP, Clough RW, et al. Combinedmodality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol 2006; 24(4): 605-611.
32. Eich HT, Staar S, Gossmann A, et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004; 58(4): 1121-1127. (Pubitemid 38314794)
33. Thomas J, Ferme C, Noordijk EM, et al. Results of the EORTCGELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma. Haematologica 2007; 92(S5): 27.
34. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20(16): 3484-3494. (Pubitemid 34894682)
35. Hoskin PJ, Smith P, Maughan TS, et al. Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol (R Coll Radiol) 2005; 17(1): 47-53. (Pubitemid 40090194)
36. Meyer RM, Ambinder RF, Stroobants S. Hodgkin's lymphoma: evolving concepts with implications for practice. Hematology Am Soc Hematol Educ Program 2004: 184-202.
37. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8 (Suppl 1): 115-118.
38. Van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12(2): 312-325. (Pubitemid 24056405)
39. Behringer K, Josting A, Schiller P, et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004; 15(7): 1079-1085. (Pubitemid 39089785)
40. Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69(5): 1241-1247.
41. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998; 46(1): 51-62. (Pubitemid 28072859)
42. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6: 225-242.
43. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assoc 1993; 270(16): 1949-1955. (Pubitemid 23312611)
44. King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996; 36(4): 881-889. (Pubitemid 27008604)
45. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20(8): 2101-2108. (Pubitemid 34408801)
46. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term causespecific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21(18): 3431-3439.
47. Nieder C, Schill S, Kneschaurek P, Molls M. Comparison of three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breasts. Radiother Oncol 2007; 82(3): 301-307. (Pubitemid 46341469)
48. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. J Am Med Assoc 2003; 290(21): 2831-2837.
49. Chronowski GM, Wilder RB, Tucker SL, et al. Analysis of in- field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55(1): 36-43.
50. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, van Putten WL, Levendag PC. Ischemic heart disease after mantle field irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 1999; 51(1): 35-42.
51. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol 2006; 78(1): 1-5. (Pubitemid 43131028)
52. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008; 26(32): 5170-5174.
53. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002; 13 (Suppl 1): 86-91.
54. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and lowdose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002; 20(14): 3081-3087.
55. Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 Trial. Int J Radiat Oncol Biol Phys 2001; 51(5): 1209-1218. (Pubitemid 33116313)
56. Kuentz M, Reyes F, Brun B, et al. Early response to chemotherapy as a prognostic factor in Hodgkin's disease. Cancer 1983; 52(5): 780-785.
57. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586. (Pubitemid 350002966)
58. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2- [18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish Study. J Clin Oncol 2007; 25(24): 3746-3752. (Pubitemid 47372616)
59. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339(21): 1506-1514.
60. Jerusalem G, Beguin Y. The place of positron emission tomography imaging in the management of patients with malignant lymphoma. Haematologica 2006; 91(4): 442-444.
61. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. J Clin Oncol 2006; 24(19): 3128-3135. (Pubitemid 46638951)
62. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 Trial. J Clin Oncol 2007; 25(23): 3495-3502. (Pubitemid 47310889)